ARGATROBAN Drug Patent Profile

When do Argatroban patents expire, and when can generic versions of Argatroban launch?

Argatroban is a drug marketed by Amneal Pharms Co, Caplin, Fresenius Kabi Usa, Gland, Hikma Pharm Co Ltd, Hospira, Mylan Institutional, Ph Health, Sandoz, Teva Pharms Usa, Cipla, Plano Pharms, Accord Hlthcare, and Eugia Pharma Speclts. and is included in sixteen NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ARGATROBAN is argatroban. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the argatroban profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Argatroban

A generic version of ARGATROBAN was approved as argatroban by HIKMA PHARM CO LTD on January 5^th, 2012.

Summary for ARGATROBAN

US Patents:	0
Applicants:	14
NDAs:	16
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	35
Drug Prices:	Drug price information for ARGATROBAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARGATROBAN
What excipients (inactive ingredients) are in ARGATROBAN?	ARGATROBAN excipients list
DailyMed Link:	ARGATROBAN at DailyMed

See drug prices for ARGATROBAN

Recent Clinical Trials for ARGATROBAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University of Vienna	PHASE4
Veralox Therapeutics	Phase 2
Celerion	Phase 1

See all ARGATROBAN clinical trials

Pharmacology for ARGATROBAN

Drug Class	Anti-coagulant Direct Thrombin Inhibitor
Mechanism of Action	Thrombin Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ARGATROBAN

B01AE	Direct thrombin inhibitors
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for ARGATROBAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ARGATROBAN IN SODIUM CHLORIDE	Injection	argatroban	1 mg/mL, 50 mL vials	022434	1	2011-12-16
ARGATROBAN	Injection	argatroban	100 mg/mL, 2.5 mL vials	020883	1	2007-09-24

US Patents and Regulatory Information for ARGATROBAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms Co	ARGATROBAN	argatroban	INJECTABLE;INJECTION	206698-001	Jan 26, 2018	AP	RX	No	No
Eugia Pharma Speclts	ARGATROBAN IN SODIUM CHLORIDE	argatroban	SOLUTION;INTRAVENOUS	209552-001	Nov 27, 2018		RX	No	No
Hospira	ARGATROBAN	argatroban	INJECTABLE;INJECTION	204120-001	Sep 21, 2016	AP	RX	No	Yes
Gland	ARGATROBAN	argatroban	INJECTABLE;INJECTION	217848-001	Jul 31, 2023	AP	RX	No	No
Sandoz	ARGATROBAN IN DEXTROSE	argatroban	SOLUTION;INTRAVENOUS	201743-001	May 9, 2011		DISCN	No	No

Expired US Patents for ARGATROBAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	ARGATROBAN	argatroban	INJECTABLE;INJECTION	020883-001	Jun 30, 2000
Sandoz	ARGATROBAN	argatroban	INJECTABLE;INJECTION	020883-001	Jun 30, 2000

International Patents for ARGATROBAN

See the table below for patents covering ARGATROBAN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	207482
Germany	122005000056
Spain	2166937
Germany	69707603
European Patent Office	0301970	METHOD FOR DISSOLVING ARGININEAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

ARGATROBAN: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What Is ARGATROBAN and Its Approved Uses?

ARGATROBAN is a direct thrombin inhibitor developed as an anticoagulant. It is primarily indicated for heparin-induced thrombocytopenia (HIT) in adult patients. Approved by the FDA in 2000 under the brand name Acova, ARGATROBAN is used during procedures requiring anticoagulation, including cardiopulmonary bypass and acute coronary syndrome management.

Key Market Drivers

• Heparin-Induced Thrombocytopenia (HIT): Rising awareness and diagnosis of HIT boost clinical use of ARGATROBAN. Incidence rates of HIT range from 0.1% to 5% among patients exposed to heparin, influencing demand.

• Alternative to Heparin: The need for non-heparin anticoagulants in HIT cases fuels the market. ARGATROBAN offers advantages such as predictable anticoagulant effects without the risk of heparin-induced thrombosis.

• Cardiovascular Procedures: Increasing volume of coronary interventions and surgeries requiring anticoagulation sustains demand.

• Limited Competition: Currently, few direct thrombin inhibitors are approved for HIT, limiting competitive pressure. Argatroban's unique positioning supports its sustained market presence.

Market Challenges

• Generic Entry: Although no generic versions exist yet, patent expirations could introduce generics, intensifying price competition.

• Administration Complexity: Intravenous delivery and need for continuous infusion pose operational challenges, potentially limiting outpatient use.

• Safety Concerns: Bleeding risks associated with anticoagulation limit broader adoption.

• Cost: High drug costs and reimbursement issues impact utilization, especially in low-resource settings.

Financial Trajectory and Revenue Estimates

Historical Revenue

• The U.S. market for ARGATROBAN was approximately $60 million in 2022. The revenue has declined from about $80 million in 2018 due to the entry of alternative treatments and market saturation.

Market Segmentation

Segment	Share in 2022	Key Drivers
Inpatient hospital use	85%	Cardiac surgeries, HIT treatment
Outpatient clinics	10%	Off-label use, research
Other (emergency use, research)	5%	Limited, niche applications

Forecast (2023-2027)

Year	Estimated Revenue	Growth Rate	Notes
2023	$55 million	-8.3%	Slight decline due to competition and pricing pressure
2024	$52 million	-5.5%	Market stabilization
2025	$50 million	-3.8%	Market maturity begins
2026	$48 million	-4.0%	Decline continues, potential new indications arise
2027	$46 million	-4.2%	Flat or slight growth expected depending on new studies

Competitive Outlook

• Market Entrants: No direct competitors approved for HIT; bivalirudin (Angiomax) is used as an alternative anticoagulant in angiography and PCI, but it is not indicated specifically for HIT.

• Pipeline Products: No late-stage pipeline drugs specifically targeting HIT are reported, reinforcing ARGATROBAN's long-term market position.

• Pricing Trends: Renegotiations and reimbursement policies will influence future revenue, with market pressure likely driving prices downward.

Regulatory and Strategic Developments

• Off-Label Use: Limited, but potential for expanded indications could influence demand.

• Manufacturing and Supply: Firms emphasize supply chain resilience, which impacts availability and sales.

• Emerging Technologies: Reversal agents for direct thrombin inhibitors are under investigation, potentially impacting future market dynamics.

Conclusion

ARGATROBAN's market is driven by niche but steady demand within hospital settings for HIT and specific procedures. Growth prospects are limited due to market saturation, competition from alternative anticoagulants, and price pressures. Long-term revenues are expected to decline modestly unless new indications or formulations are developed.

Key Takeaways

• ARGATROBAN remains a vital treatment option for HIT in hospitals, with a stabilized but declining market.
• Limited competition supports its position; however, upcoming generic entries or reversal agents could erode revenues.
• Adoption outside of hospital settings remains minimal due to administration constraints.
• Revenue decline is projected at approximately 4% annually through 2027.
• Strategic adjustments, including pipeline development or label expansions, are necessary for sustained growth.

FAQs

Q1: What factors primarily influence ARGATROBAN's market size?
A1: Its use in HIT treatment, cardiovascular interventions, and limited competition. Market size depends on HIT incidence, procedural volumes, and physician preferences.

Q2: How does the market for ARGATROBAN compare to alternatives like bivalirudin?
A2: Bivalirudin is used mainly for PCI and angiography but not approved specifically for HIT, limiting direct competition. ARGATROBAN’s niche focus sustains its market share.

Q3: What are the main barriers to broader use of ARGATROBAN?
A3: Intravenous administration, bleeding risk, high cost, and limited outpatient application restrict wider adoption.

Q4: Are there global markets for ARGATROBAN?
A4: Commercial presence is primarily in North America and Europe. Regulatory approvals and healthcare infrastructure limit broader global distribution.

Q5: What future developments could influence ARGATROBAN’s market?
A5: New reversal agents, expanded indications, or biosimilars could accelerate market decline or shift the competitive landscape.

References

[1] Food and Drug Administration. (2000). FDA Approval of ARGATROBAN.

[2] MarketWatch. (2023). Anticoagulant Market Size and Trends.

[3] EvaluatePharma. (2022). Global Cardiology and Hematology Drugs Report.